Holger H.H. Erb

1.6k total citations
58 papers, 1.2k citations indexed

About

Holger H.H. Erb is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Holger H.H. Erb has authored 58 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Holger H.H. Erb's work include Prostate Cancer Treatment and Research (31 papers), Cancer, Lipids, and Metabolism (12 papers) and Cancer-related Molecular Pathways (8 papers). Holger H.H. Erb is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Cancer, Lipids, and Metabolism (12 papers) and Cancer-related Molecular Pathways (8 papers). Holger H.H. Erb collaborates with scholars based in Germany, Austria and United Kingdom. Holger H.H. Erb's co-authors include Zoran Čulig, Frédéric R. Santer, Su Jung Oh, Martin Puhr, Julia Hoefer, Georg Schäfer, Helmut Klocker, Rhiannon V. McNeill, Christian Thomas and Isabel Heidegger and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Holger H.H. Erb

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holger H.H. Erb Germany 17 626 453 393 366 145 58 1.2k
Yuanjie Niu China 20 703 1.1× 582 1.3× 413 1.1× 279 0.8× 87 0.6× 49 1.2k
June Escara‐Wilke United States 16 1.2k 1.9× 554 1.2× 333 0.8× 481 1.3× 245 1.7× 25 1.8k
Frédéric R. Santer Austria 21 721 1.2× 472 1.0× 318 0.8× 460 1.3× 206 1.4× 40 1.4k
Yuanjie Niu China 21 729 1.2× 748 1.7× 410 1.0× 306 0.8× 102 0.7× 41 1.4k
Timothy G. Whitsett United States 18 527 0.8× 239 0.5× 266 0.7× 247 0.7× 81 0.6× 35 996
David James VanderWeele United States 15 485 0.8× 355 0.8× 262 0.7× 300 0.8× 108 0.7× 57 1.0k
Cai Bowen United States 12 573 0.9× 360 0.8× 198 0.5× 247 0.7× 66 0.5× 19 882
Yu-Mei Feng China 21 847 1.4× 146 0.3× 383 1.0× 466 1.3× 77 0.5× 41 1.3k
Guanglong Jiang United States 18 641 1.0× 162 0.4× 289 0.7× 370 1.0× 101 0.7× 52 1.1k
Dimitra Tsavachidou United States 10 395 0.6× 203 0.4× 241 0.6× 180 0.5× 74 0.5× 15 703

Countries citing papers authored by Holger H.H. Erb

Since Specialization
Citations

This map shows the geographic impact of Holger H.H. Erb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger H.H. Erb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger H.H. Erb more than expected).

Fields of papers citing papers by Holger H.H. Erb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger H.H. Erb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger H.H. Erb. The network helps show where Holger H.H. Erb may publish in the future.

Co-authorship network of co-authors of Holger H.H. Erb

This figure shows the co-authorship network connecting the top 25 collaborators of Holger H.H. Erb. A scholar is included among the top collaborators of Holger H.H. Erb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger H.H. Erb. Holger H.H. Erb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Erb, Holger H.H., et al.. (2024). Glutamine Metabolism and Prostate Cancer. Cancers. 16(16). 2871–2871. 10 indexed citations
3.
Erb, Holger H.H., et al.. (2024). Utilization of sperm cryopreservation in patients with testicular cancer. Journal of Cancer Research and Clinical Oncology. 150(4). 201–201. 3 indexed citations
4.
Brandt, Maximilian Peter, Olesya Vakhrusheva, Hubert Hackl, et al.. (2024). Inhibition of the Sterol Regulatory Element Binding Protein SREBF-1 Overcomes Docetaxel Resistance in Advanced Prostate Cancer. American Journal Of Pathology. 194(11). 2150–2162. 1 indexed citations
5.
6.
Sander, Caroline, Martin Weiß, Eva K. Egger, et al.. (2023). Pleiotropic Devitalization of Renal Cancer Cells by Non-Invasive Physical Plasma: Characterization of Molecular and Cellular Efficacy. Cancers. 15(2). 481–481. 5 indexed citations
7.
Sommer, Ulrich, Marianne Großer, Daniela E. Aust, et al.. (2023). PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?. Anticancer Research. 43(10). 4365–4371.
8.
Hönscheid, Pia, Christian Sperling, Korinna Jöhrens, et al.. (2022). Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue. Life. 12(2). 240–240. 5 indexed citations
9.
Sommer, Ulrich, et al.. (2022). The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity. Current Issues in Molecular Biology. 44(2). 597–608. 9 indexed citations
10.
Peitzsch, Claudia, et al.. (2022). Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines. International Journal of Molecular Sciences. 24(1). 666–666. 12 indexed citations
11.
Erb, Holger H.H., Claudia Peitzsch, Anna Dubrovska, et al.. (2022). Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. Journal of Cancer Research and Clinical Oncology. 148(6). 1313–1324. 1 indexed citations
12.
Thomas, Christian, Martin Baunacke, Holger H.H. Erb, et al.. (2021). Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?. Cancers. 14(1). 8–8. 11 indexed citations
13.
Erb, Holger H.H., Florian Handle, Igor Tsaur, et al.. (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE. 15(8). e0237248–e0237248. 14 indexed citations
14.
Erb, Holger H.H., et al.. (2019). PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target. PLoS ONE. 14(10). e0224085–e0224085. 2 indexed citations
15.
Handle, Florian, Martin Puhr, Georg Schaefer, et al.. (2018). The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. Molecular Cancer Therapeutics. 17(12). 2722–2731. 36 indexed citations
16.
Juengel, Eva, Holger H.H. Erb, Axel Haferkamp, et al.. (2018). Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors. Cancer Letters. 435. 121–126. 28 indexed citations
17.
Handle, Florian, Holger H.H. Erb, Birgit Luef, et al.. (2016). SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. Molecular Cancer Research. 14(6). 574–585. 36 indexed citations
18.
Santer, Frédéric R., Holger H.H. Erb, & Rhiannon V. McNeill. (2015). Therapy escape mechanisms in the malignant prostate. Seminars in Cancer Biology. 35. 133–144. 54 indexed citations
19.
Erb, Holger H.H., Frédéric R. Santer, & Zoran Čulig. (2012). Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer. Cancer Research. 72(8_Supplement). 3350–3350. 8 indexed citations
20.
Santer, Frédéric R., Su Jung Oh, Holger H.H. Erb, et al.. (2011). Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines. Molecular Cancer Therapeutics. 10(9). 1644–1655. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuanjie Niu Breakdown of academic impact, for papers by June Escara‐Wilke Breakdown of academic impact, for papers by Frédéric R. Santer Breakdown of academic impact, for papers by Yuanjie Niu Breakdown of academic impact, for papers by Timothy G. Whitsett Breakdown of academic impact, for papers by David James VanderWeele Breakdown of academic impact, for papers by Cai Bowen Breakdown of academic impact, for papers by Yu-Mei Feng Breakdown of academic impact, for papers by Guanglong Jiang Breakdown of academic impact, for papers by Dimitra Tsavachidou
Rankless by CCL
2026